Dr. Avi B. Markowitz, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
301 University Blvd
Galveston, TX 77555
Who else practices at this address →
Galveston County includes primary care (1% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of California, San Francisco School of Medicine (1981)
- Years since graduation
- 45
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 68
Licensed in Texas since 1988, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1981Medical school: University of California, San Francisco School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
TX license H3701 (first issued 1988; active) -
Medical Oncology Physician
TX license H3701 (first issued 1988; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Texas Medical Branch Galveston Galveston, TX
Medical groups
- Utmb Faculty Group Practice (1,101 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 68
- Services billed
- 143
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 78 | 46 |
| Established patient office or other outpatient visit, 40-54 minutes | 67 | 32 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 21 | 20 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Anastrozole Other prescribers in Galveston, TX | 95 |
| Imbruvica (ibrutinib) | 44 |
| Verzenio (abemaciclib) | 38 |
| Letrozole Other prescribers in Galveston, TX | 23 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Galveston, TX | 18 |
| Prochlorperazine Maleate Other prescribers in Galveston, TX | 18 |
| Ondansetron Odt (ondansetron) Other prescribers in Galveston, TX | 14 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $650 in research payments for these studies, mostly to the institutions running them.
- A phase II single arm open label study of nilotinib discontinuation after achieving and maintaining MR four and a half
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.